X-linked inhibitor of apoptosis inhibition sensitizes acute myeloid leukemia cell response to TRAIL and chemotherapy through potentiated induction of proapoptotic machinery

Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia

(2017) Hubert Hackl et al.   Journal of Hematology & Oncology

Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemia

(2017) Jianbiao Zhou et al.   Journal of Hematology & Oncology

A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance

(2017) Lina Y. Dimberg et al.   MOLECULAR CANCER RESEARCH

Onto better TRAILs for cancer treatment

(2016) D de Miguel et al.   CELL DEATH AND DIFFERENTIATION

Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?

(2016) S Baig et al.   Cell Death & Disease

‘Acute myeloid leukemia: a comprehensive review and 2016 update’

(2016) I De Kouchkovsky et al.   Blood Cancer Journal

Acute Myeloid Leukemia With Myelodysplasia-Related Changes

(2015) James Vardiman et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

5-Fluorouracil preferentially sensitizes mutant KRAS non-small cell lung carcinoma cells to TRAIL-induced apoptosis

(2015) Haizhen Wang et al.   Molecular Oncology

p53mutations in colorectal cancer- molecular pathogenesis and pharmacological reactivation

(2015) Xiao-Lan Li   WORLD JOURNAL OF GASTROENTEROLOGY

Aberrant nuclear factor-kappa B activity in acute myeloid Leukemia: from molecular pathogenesis to therapeutic target

(2015) Jianbiao Zhou et al.   Oncotarget

Getting TRAIL back on track for cancer therapy

(2014) J Lemke et al.   CELL DEATH AND DIFFERENTIATION

Revisiting caspases in sepsis

(2014) M Aziz et al.   Cell Death & Disease

Tumor-targeting TRAIL expression mediated by miRNA response elements suppressed growth of uveal melanoma cells

(2013) Jia Liu et al.   Molecular Oncology

Fas death receptor signalling: roles of Bid and XIAP

(2011) T Kaufmann et al.   CELL DEATH AND DIFFERENTIATION

Addition of AEG35156 XIAP Antisense Oligonucleotide in Reinduction Chemotherapy Does Not Improve Remission Rates in Patients With Primary Refractory Acute Myeloid Leukemia in a Randomized Phase II Study

(2011) Aaron D. Schimmer et al.   Clinical Lymphoma Myeloma & Leukemia

Exploiting cellular pathways to develop new treatment strategies for AML

(2010) Amir T. Fathi et al.   CANCER TREATMENT REVIEWS

Mechanisms of Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine in Pediatric Acute Myeloid Leukemia

(2010) C. Xie et al.   CLINICAL CANCER RESEARCH

Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia

(2009) Aaron D. Schimmer et al.   JOURNAL OF CLINICAL ONCOLOGY

ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside

(2009) Jianbiao Zhou et al.   Journal of Hematology & Oncology

Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells

(2008) P. L. Tazzari et al.   CANCER RESEARCH

The extrinsic cell death pathway and the élan mortel

(2008) D Wallach et al.   CELL DEATH AND DIFFERENTIATION

Deregulation of the Mitochondrial Apoptotic Machinery and Development of Molecular Targeted Drugs in Acute Myeloid Leukemia

(2008) G. Poeta et al.   CURRENT CANCER DRUG TARGETS

In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor

(2008) Jianbiao Zhou et al.   LEUKEMIA RESEARCH